Skip to main content

Novel Rx

Repetitive Transcranial Magnetic Stimulation in Fibromyalgia

A randomized, sham-controlled trial has shown that repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.

Read Article
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/sQMITpZbn3 https://t.co/up474pecNL
Dr. John Cush @RheumNow( View Tweet )
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This condition results from autosomal recessive mutations in the MEFV gene, which codes for Pyrin, a crucial component of the NLRP3 inflammasome. These genetic https://t.co/XNV89LW893
Dr. John Cush @RheumNow( View Tweet )
2024 Rheumatology Year in Review 2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians. https://t.co/JjG8oYTkKQ https://t.co/YgHMMiAQ9Z
Dr. John Cush @RheumNow( View Tweet )
Mizoribine Effective in Lupus Nephritis A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis. https://t.co/OWnGly4TUX https://t.co/zbPPH1n4lU
Dr. John Cush @RheumNow( View Tweet )
J&J announced the FDA jas granted the investigational drug, nipocalimab (FcRn recpt Ab), with Fast Track designation for its study in adult patients with moderate-to-severe Sjögren’s disease https://t.co/5rEYHkGVp2 https://t.co/ny2dv6Jtr5
Dr. John Cush @RheumNow( View Tweet )
2024 Rheumatology Year in Review 2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians. https://t.co/JjG8oYTkKQ https://t.co/YgHMMiAQ9Z
Dr. John Cush @RheumNow( View Tweet )
The FDA has approved guselkumab(Tremfya) for both subcutaneous (SC) and intravenous (IV) induction therapy treatment of adults with moderately to severely active Crohn’s disease (CD). It is the only IL-23 inhbitor available for SC and IV use in CD https://t.co/ekXRVOwNnS https://t.co/6zveRR5WjD
Dr. John Cush @RheumNow( View Tweet )

Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis

A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and required major changes in treatment.

The aim of this study was to analyze disease activity and

Read Article
Mizoribine Effective in Lupus Nephritis A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis. https://t.co/OS3yaJlEm7 https://t.co/1YcyfarF09
Dr. John Cush @RheumNow( View Tweet )
J&J announced the FDA jas granted the investigational drug, nipocalimab (FcRn recpt Ab), with Fast Track designation for its study in adult patients with moderate-to-severe Sjögren’s disease https://t.co/TB2cESMLQi https://t.co/IC7PQP2fcx
Dr. John Cush @RheumNow( View Tweet )
Glucocorticoid Toxicity Index Dr. John Stone has led the effort to develop the GTI - glucocorticoid toxicity index. In this review article he acknowledges the need and benefit of steroids, but details a novel means to identify and limit the untoward effects of glucorticoids… https://t.co/xR8D4Jpjfv https://t.co/LyfHrbneTO
Dr. John Cush @RheumNow( View Tweet )
2024 Rheumatology Year in Review 2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians. https://t.co/XuEG8Hrc9e https://t.co/ja5OoZXdWo
Dr. John Cush @RheumNow( View Tweet )
Stelara Biosimilar Steqeyma Launches at 85% Discount https://t.co/2ZR7LMq1JT https://t.co/coHj1jh8JB
Dr. John Cush @RheumNow( View Tweet )
Sobi announced it has submitted to FDA a supplemental (sBLA) for Gamifant (emapalumab-Izsg) for use in adult & kids w/ hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease with an inadequate response glucocorticoids, or with recurrent… https://t.co/a3I1fzHLdl https://t.co/WTFAs5PLWF
Dr. John Cush @RheumNow( View Tweet )
In 7 Major countries worldwide, Still’s Disease Treatment Markets were valued at USD 1.33 Billion in the year 2024 and is projected to reach USD 1.92 Billion by 2035. https://t.co/zjrd7RgHkj https://t.co/iqFp877wnN
Dr. John Cush @RheumNow( View Tweet )
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/qZb8OKjPpw https://t.co/Exr8u6QkNc
Dr. John Cush @RheumNow( View Tweet )

World Changers (3.14.2025)

Dr Jack Cush and his podcast friends are out to change the world. Here is his weekly review of the news and journal reports from the past week on RheumNow.

Read Article
Sobi announced it has submitted to FDA a supplemental (sBLA) for Gamifant (emapalumab-Izsg) for use in adult & kids w/ hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease with an inadequate response glucocorticoids, or with recurrent… https://t.co/PLpcD5jzxH https://t.co/0LUe9bXaYS
Dr. John Cush @RheumNow( View Tweet )

Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs

A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (

Read Article

2024 Rheumatology Year in Review

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list

Read Article
Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to deucravacitinib in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 15 in 684 moderate-to-severe plaque PsO pts… https://t.co/GYK604kJ9u https://t.co/Ao1BpL1Qxt
Dr. John Cush @RheumNow( View Tweet )
The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (tocilizumab). https://t.co/ukMDwtgUhw https://t.co/htDVWKbu3n
Dr. John Cush @RheumNow( View Tweet )
Congratulations to Dr. Mehmet Hocaoglu (University of Pittsburgh) on being awarded a 2024 Rheumatoid Arthritis Research Program grant to investigate the unique and shared risk factors between patients with preclinical rheumatoid arthritis and patients with RA.… https://t.co/eF4yb3Hxsj https://t.co/MLNWKFiCiU
Dr. John Cush @RheumNow( View Tweet )
BMS announced new data from Phase 3 POETYK PsA-2 trial - Sotyktu (deucravacitinib)vs apremilast vs PBO in PsA w/ higher ACR20 vs PBO at Week 16 (54% vs 39%). AEs led to discontinuation in 1.3% (PBO), 2.2% (Deuc) and 10.5% (apremilast). https://t.co/NAa2JigkZN https://t.co/mvaQXfjShd
Dr. John Cush @RheumNow( View Tweet )
×